Immunotherapy Toxicity Management in NSCLC – OncLive
|
Immunotherapy Toxicity Management in NSCLC
OncLive Everett Vokes, MD: Briefly, Roy, can you comment on toxicities with checkpoint inhibitors? What are toxicities community oncologists should know? Roy Herbst, MD, PhD: Right. And that’s the reason why we really want to make sure we have some efficacy. |
|
Next Steps in Research for Immunotherapy for HNSCC
OncLive So, I think that there’s going to be a lot of room for looking at combinations of existing therapies, whether they’re conventional DNA damage approaches or they’re targeted therapies with immunotherapy. I would encourage the people who are watching … |
|
Poseida’s CAR T-cell Therapy Eradicates Previously Incurable Prostate Cancer in Mice
Prostate Cancer News Today Poseida Therapeutics’ CAR T-cell therapy P-PSMA-101 eradicated a previously incurable type of human prostate cancer implanted in mice, the company reported. Another CAR T-cell therapy that has reached doctor’s offices has failed to counter the cancer, … |